Clinical trials: Oral Phase
Infection, Human Immunodeficiency Virus, HIV Infections
Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine
The study is designed to select a dose of GSK1265744 primarily on the basis of antiviral activity and tolerability in HIV-1 infected, antiretroviral naive subjects.
- Trial name
- NCT01641809
- Testing
- GSK1265744 10 mg, GSK1265744 30 mg, GSK1265744 60 mg
- Where
- 48 sites in United States, Canada
- Volunteers
- 244 people
- Sponsor
- ViiV Healthcare
Acute Leukemias
Study of Efficacy and Safety of LDE225 in Adult Patients With Relapsed/Refractory Acute Leukemia
The study will evaluate the efficacy, safety and tolerability of two dosing schedules of LDE225 in patients with relapsed/refractory acute leukemia or elderly patients with untreated acute leukemia.
- Trial name
- NCT01826214
- Testing
- LDE225
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research
The present trial will investigate the efficacy and safety of nintedanib in combination with docetaxel as compared to placebo in combination with docetaxel in patients with stage IIIB/IV or recurrent NSCLC of adenocarcinoma…
- Trial name
- NCT02231164
- Testing
- docetaxel, nintedanib
- Where
- 13 sites in United States, Georgia and 1 more
- Volunteers
- 12 people
- Sponsor
- Boehringer Ingelheim
Primary Myelofibrosis, Thrombocytosis
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
The purpose of this phase Ib/II clinical trial was to: a) evaluate the safety of the co-administration of LDE225 and INC424 in myelofibrosis patients and establish a maximum tolerated dose and/or Recommended Phase II dose of the…
- Conditions
- Primary Myelofibrosis, Thrombocytosis, Essential Thrombocythemia, Polycythemia Vera
- Trial name
- NCT01787552
- Testing
- LDE225, INC424
- Where
- 18 sites in Australia, Belgium and 9 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumors, Cancer
Trial of MSC1936369B in Subjects With Solid Tumors
This is a first in man trial with a primary objective being the determination of the Maximum Tolerated dose (MTD) and the dose-limiting toxicity (DLT) in several regimens of MEK inhibitor MSC1936369B administered orally once a…
- Trial name
- NCT00982865
- Testing
- MSC1936369B
- Where
- 9 sites in Australia, Belgium and 2 more
- Volunteers
- 182 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Glioblastoma, MGMT-Unmethylated Glioblastoma
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
This Phase I study investigated the side-effects and best dose of microtubule-targeted agent BAL101553 when given together with radiation therapy in treating patients with newly-diagnosed O6-methylguanine-DNA methyltransferase…
- Trial name
- NCT03250299
- Testing
- Microtubule-Targeted Agent BAL101553, Radiation Therapy
- Where
- 8 sites in United States
- Volunteers
- 26 people
- Sponsor
- Basilea Pharmaceutica
Irritable Bowel Syndrome
A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome
A study to evaluate the effectiveness of oral doses of Blautix in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT03721107
- Testing
- Blautix
- Where
- 34 sites in United States, Ireland and 1 more
- Volunteers
- 366 people
- Sponsor
- 4D pharma plc
Japanese Healthy Adult Male Participants
A Phase 1, Bio-equivalence Study of TAK-536 Pediatric Formulation
The purpose of this study is to evaluate the bio-equivalence of a single oral administration of TAK-536 pediatric formulation (granules) in comparison with a TAK-536 commercial formulation (tablet) in Japanese healthy adult male…
- Trial name
- NCT03042299
- Testing
- TAK-536
- Where
- Japan
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Takeda
Pulmonary Arterial Hypertension
Beraprost-314d Added-on to Tyvaso® (BEAT)
This is a multicenter, double-blind, randomized, placebo-controlled Phase 3 study, to assess the efficacy and safety of BPS-314d-MR when added-on to inhaled treprostinil (Tyvaso®)in patients with pulmonary arterial hypertension.
- Trial name
- BEAT (NCT01908699)
- Testing
- Beraprost Sodium 314d Modified Release Tablets
- Where
- 75 sites in United States, Israel
- Volunteers
- 273 people
- Sponsor
- Lung Biotechnology PBC
Healthy Participants
A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants
This study will be the first time PF-07258669 is administered to humans. The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of PF-07258669 following administration of single oral doses to…
- Trial name
- NCT04628793
- Testing
- PF-07258669
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Pfizer
Eosinophilic Esophagitis
A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for active eosinophilic esophagitis (EoE) in adult participants.
- Trial name
- VOYAGE (NCT04682639)
- Testing
- Etrasimod
- Where
- 256 sites in United States, Australia and 6 more
- Volunteers
- 108 people
- Sponsor
- Pfizer
Migraine, With or Without Aura
Trial in Adult Subjects With Acute Migraines
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant ODT) versus placebo in subjects with Acute Migraines.
- Trial name
- NCT03461757
- Testing
- Rimegepant
- Where
- 69 sites in United States
- Volunteers
- 1,811 people
- Sponsor
- Pfizer
Early Parkinson Disease (Early PD)
Efficacy, Safety, Tolerability of Pramipexol ER Versus Pramipexol IR Versus Placebo in Early PD Patients
The objectives of this trial conducted in early Parkinson's Disease (PD) patients are to determine the efficacy (as measured by the change from baseline to the end of the maintenance phase in the total score for the Unified…
- Trial name
- NCT00479401
- Testing
- Pramipexol Extended Release, Pramipexol Immediate Release
- Where
- 95 sites in United States, Argentina and 12 more
- Volunteers
- 539 people
- Sponsor
- Boehringer Ingelheim
Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects, Apathy
Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers
This is a phase I trial evaluating the pharmacokinetics of single ascending oral doses of IRL757 in healthy elderly volunteers.
- Trial name
- NCT06699628
- Testing
- IRL757
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Integrative Research Laboratories AB
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
SB-715992 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This phase II trial is studying how well SB-715992 works in treating patients with recurrent or metastatic head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00095628
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes Mellitus, Type 2
Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients…
- Trial name
- NCT01159600
- Testing
- BI 10773
- Where
- 148 sites in United States, Canada and 10 more
- Volunteers
- 1,504 people
- Sponsor
- Boehringer Ingelheim
Safety, Tolerability
A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.
This is a Phase I, first-in-human (FIH), randomized, single-blind, placebo-controlled, single ascending dose sequential group study in healthy male subjects.
- Conditions
- Safety, Tolerability, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT02512575
- Testing
- AZD9567 Monohydrat, Prednisolone
- Where
- Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma
Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer
This randomized phase II trial studies how well multi-epitope folate receptor alpha peptide vaccine, sargramostim (GM-CSF), and cyclophosphamide work to prevent the recurrence of stage 1-3 triple negative breast cancer.
- Conditions
- Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7
- Trial name
- NCT03012100
- Testing
- Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine
- Where
- 12 sites in United States
- Volunteers
- 280 people
- Sponsor
- Academic and Community Cancer Research United
Neoplasms
Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma
First in human, open-label, dose escalation (Phase I) and expansion study (Phase 2a) of oral lisavanbulin (BAL101553) in adult patients with advanced solid tumors and adult patients with recurrent or progressive glioblastoma…
- Trial name
- NCT02490800
- Testing
- Lisavanbulin Phase 1 dose escalation portion, Lisavanbulin Phase 2a expansion portion
- Where
- 13 sites in Belgium, Germany and 2 more
- Volunteers
- 72 people
- Sponsor
- Basilea Pharmaceutica
Arthritis, Rheumatoid
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with…
- Trial name
- NCT02092467
- Testing
- tofacitinib, adalimumab, etanercept
- Where
- 345 sites in United States, Argentina and 28 more
- Volunteers
- 4,372 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.